25 XP   0   0   10

Neurocrine Biosciences Inc
Buy, Hold or Sell?

Let's analyse Neurocrine together

PenkeI guess you are interested in Neurocrine Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Neurocrine Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Neurocrine Biosciences Inc

I send you an email if I find something interesting about Neurocrine Biosciences Inc.

Quick analysis of Neurocrine (30 sec.)










What can you expect buying and holding a share of Neurocrine? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$21.82
Expected worth in 1 year
$26.69
How sure are you?
62.5%

+ What do you gain per year?

Total Gains per Share
$4.88
Return On Investment
3.5%

For what price can you sell your share?

Current Price per Share
$138.97
Expected price per share
$129.15 - $148.37
How sure are you?
50%

1. Valuation of Neurocrine (5 min.)




Live pricePrice per Share (EOD)

$138.97

Intrinsic Value Per Share

$22.12 - $47.55

Total Value Per Share

$43.94 - $69.37

2. Growth of Neurocrine (5 min.)




Is Neurocrine growing?

Current yearPrevious yearGrowGrow %
How rich?$2.2b$1.5b$426.1m21.9%

How much money is Neurocrine making?

Current yearPrevious yearGrowGrow %
Making money$62.4m$38.6m$23.8m38.1%
Net Profit Margin12.1%9.8%--

How much money comes from the company's main activities?

3. Financial Health of Neurocrine (5 min.)




What can you expect buying and holding a share of Neurocrine? (5 min.)

Welcome investor! Neurocrine's management wants to use your money to grow the business. In return you get a share of Neurocrine.

What can you expect buying and holding a share of Neurocrine?

First you should know what it really means to hold a share of Neurocrine. And how you can make/lose money.

Speculation

The Price per Share of Neurocrine is $138.97. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neurocrine.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neurocrine, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $21.82. Based on the TTM, the Book Value Change Per Share is $1.22 per quarter. Based on the YOY, the Book Value Change Per Share is $0.78 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neurocrine.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps1.441.0%0.610.4%0.390.3%0.470.3%0.130.1%
Usd Book Value Change Per Share2.021.4%1.220.9%0.780.6%0.850.6%0.520.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.021.4%1.220.9%0.780.6%0.850.6%0.520.4%
Usd Price Per Share131.76-109.95-104.22-100.15-75.85-
Price to Earnings Ratio22.81-12.22-24.17-14.74--27.59-
Price-to-Total Gains Ratio65.39--1,743.23-254.29--254.69--97.78-
Price to Book Ratio6.04-5.70-6.85-9.88-11.90-
Price-to-Total Gains Ratio65.39--1,743.23-254.29--254.69--97.78-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share138.97
Number of shares7
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.220.85
Usd Total Gains Per Share1.220.85
Gains per Quarter (7 shares)8.535.95
Gains per Year (7 shares)34.1323.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10342402414
20685804838
301029207162
4013712609586
501711600119110
602051940143134
702392280166158
802732620190182
903072960214206
1003413300238230

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%18.022.00.045.0%33.077.02.029.5%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%17.03.00.085.0%25.015.00.062.5%53.058.01.047.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.0112.00.0%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%17.03.00.085.0%25.015.00.062.5%53.058.01.047.3%

Fundamentals of Neurocrine

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-11 15:34:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Neurocrine Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Neurocrine earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Neurocrine to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 28.7% means that $0.29 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neurocrine Biosciences Inc:

  • The MRQ is 28.7%. The company is making a huge profit. +2
  • The TTM is 12.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ28.7%TTM12.1%+16.6%
TTM12.1%YOY9.8%+2.2%
TTM12.1%5Y13.7%-1.6%
5Y13.7%10Y-44.6%+58.3%
1.1.2. Return on Assets

Shows how efficient Neurocrine is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Neurocrine to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.5% Return on Assets means that Neurocrine generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neurocrine Biosciences Inc:

  • The MRQ is 4.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.0%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.5%TTM2.0%+2.6%
TTM2.0%YOY1.7%+0.3%
TTM2.0%5Y2.2%-0.3%
5Y2.2%10Y-1.6%+3.9%
1.1.3. Return on Equity

Shows how efficient Neurocrine is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Neurocrine to the Drug Manufacturers - Specialty & Generic industry mean.
  • 6.6% Return on Equity means Neurocrine generated $0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neurocrine Biosciences Inc:

  • The MRQ is 6.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 2.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ6.6%TTM2.8%+3.8%
TTM2.8%YOY2.4%+0.5%
TTM2.8%5Y3.3%-0.5%
5Y3.3%10Y-1.7%+5.1%

1.2. Operating Efficiency of Neurocrine Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Neurocrine is operating .

  • Measures how much profit Neurocrine makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Neurocrine to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 29.2% means the company generated $0.29  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neurocrine Biosciences Inc:

  • The MRQ is 29.2%. The company is operating very efficient. +2
  • The TTM is 11.1%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ29.2%TTM11.1%+18.1%
TTM11.1%YOY15.5%-4.4%
TTM11.1%5Y19.1%-8.0%
5Y19.1%10Y-43.0%+62.1%
1.2.2. Operating Ratio

Measures how efficient Neurocrine is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.71 means that the operating costs are $0.71 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 0.708. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.798. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.708TTM0.798-0.090
TTM0.798YOY0.842-0.044
TTM0.7985Y0.778+0.020
5Y0.77810Y1.456-0.678

1.3. Liquidity of Neurocrine Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Neurocrine is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.45 means the company has $2.45 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 2.454. The company is able to pay all its short-term debts. +1
  • The TTM is 2.810. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.454TTM2.810-0.356
TTM2.810YOY3.193-0.383
TTM2.8105Y4.219-1.409
5Y4.21910Y9.256-5.036
1.3.2. Quick Ratio

Measures if Neurocrine is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Neurocrine to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 3.44 means the company can pay off $3.44 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 3.438. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.253. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.438TTM4.253-0.815
TTM4.253YOY4.371-0.118
TTM4.2535Y6.292-2.039
5Y6.29210Y14.799-8.507

1.4. Solvency of Neurocrine Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Neurocrine assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Neurocrine to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.31 means that Neurocrine assets are financed with 31.4% credit (debt) and the remaining percentage (100% - 31.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 0.314. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.297. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.314TTM0.297+0.017
TTM0.297YOY0.300-0.003
TTM0.2975Y0.382-0.086
5Y0.38210Y0.323+0.060
1.4.2. Debt to Equity Ratio

Measures if Neurocrine is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Neurocrine to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 45.7% means that company has $0.46 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 0.457. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.423. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.457TTM0.423+0.034
TTM0.423YOY0.431-0.009
TTM0.4235Y0.666-0.243
5Y0.66610Y0.580+0.085

2. Market Valuation of Neurocrine Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Neurocrine generates.

  • Above 15 is considered overpriced but always compare Neurocrine to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 22.81 means the investor is paying $22.81 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neurocrine Biosciences Inc:

  • The EOD is 24.063. Based on the earnings, the company is fair priced.
  • The MRQ is 22.815. Based on the earnings, the company is fair priced.
  • The TTM is 12.224. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD24.063MRQ22.815+1.248
MRQ22.815TTM12.224+10.591
TTM12.224YOY24.171-11.947
TTM12.2245Y14.739-2.515
5Y14.73910Y-27.591+42.330
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Neurocrine Biosciences Inc:

  • The EOD is 30.094. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 28.533. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 9.320. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD30.094MRQ28.533+1.561
MRQ28.533TTM9.320+19.213
TTM9.320YOY4.469+4.852
TTM9.3205Y-12.647+21.967
5Y-12.64710Y-14.650+2.003
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Neurocrine is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Neurocrine Biosciences Inc:

  • The EOD is 6.369. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.039. Based on the equity, the company is overpriced. -1
  • The TTM is 5.700. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.369MRQ6.039+0.330
MRQ6.039TTM5.700+0.339
TTM5.700YOY6.853-1.154
TTM5.7005Y9.876-4.177
5Y9.87610Y11.898-2.021
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Neurocrine Biosciences Inc.

3.1. Institutions holding Neurocrine Biosciences Inc

Institutions are holding 95.357% of the shares of Neurocrine Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc13.71540.0459136478912764932.0678
2023-12-31Vanguard Group Inc9.75840.02897103281504851.5741
2023-12-31State Street Corporation4.08340.02640633362268295.9124
2023-09-30Point72 Asset Management, L.P.2.59090.8463257812824667702215.1709
2023-12-31Bellevue Group AG2.44254.89862430500-153050-5.924
2023-12-31Morgan Stanley - Brokerage Accounts2.33780.027232629440221520.9043
2023-12-31Renaissance Technologies Corp1.99840.4056198854639838225.0529
2023-12-31JPMorgan Chase & Co1.74410.0221735543-75694-4.1791
2023-12-31Geode Capital Management, LLC1.63120.02231623124684944.4058
2023-12-31HHG PLC1.5590.12191551367-165687-9.6495
2023-12-31T. Rowe Price Associates, Inc.1.48430.0262147694929729925.2023
2023-12-31Goldman Sachs Group Inc1.39010.0164138326459630975.7742
2023-12-31Dodge & Cox1.2660.105412597441046142489.7623
2023-12-31DSM Capital Partners LLC1.22812.46241222009-2008-0.1641
2023-12-31Pictet Asset Manangement SA1.21930.1763121331316986316.279
2023-09-30Deerfield Management Co1.21572.9984120971400
2023-12-31Wellington Management Company LLP1.20550.02951199542-128397-9.6689
2023-12-31Rock Springs Capital Management LP1.20193.87931196000-40000-3.2362
2023-12-31Brown Advisory Holdings Inc1.11890.20621113413238312.1872
2023-12-31Armistice Capital, LLC1.05321.88511048000-168365-13.8417
Total 54.244118.228853977005+5389911+10.0%

3.2. Funds holding Neurocrine Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv3.11690.02613101574-7433-0.2391
2024-03-28iShares Core S&P Mid-Cap ETF3.11170.50213096364-1574-0.0508
2023-09-30BB Biotech AG Ord2.56711.75582554350-35650-1.3764
2024-02-29Vanguard Small Cap Index2.5450.2352532453234340.934
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.45940.1856145219922360.1542
2024-02-29Vanguard Small Cap Growth Index Inv1.42780.53091420781216311.546
2024-02-29SPDR® S&P MIDCAP 400 ETF Trust0.78860.486778474229520.3776
2024-03-28iShares MSCI USA Min Vol Factor ETF0.73280.408772917000
2024-03-28iShares Biotechnology ETF0.73081.3143727163-1265-0.1737
2023-12-31Dodge & Cox Stock I0.69860.0907695148552818388.4058
2023-12-31Eagle Mid-Cap Growth - Institutional0.69141.075568795912680.1847
2024-03-28iShares S&P Mid-Cap 400 Growth ETF0.66030.96657086-2587-0.3922
2024-02-29JPMorgan Mid Cap Growth I0.65950.765465622200
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.59270.1841589753157002.7349
2024-02-29Hartford MidCap Y0.58931.1784586362-2721-0.4619
2024-02-29Fidelity Extended Market Index0.55730.188555458631250.5667
2024-03-28SPDR® S&P Biotech ETF0.55151.002454878869201.2771
2023-12-31Carillon Eagle Mid Cap Growth A0.53561.084453296800
2023-12-31T. Rowe Price Health Sciences0.51510.459512523266815108.5903
2023-12-31Janus Henderson US SMID Cap Growth0.48120.929147883000
Total 23.012523.362722899021+845669+3.7%

3.3. Insider Transactions

Insiders are holding 0.999% of the shares of Neurocrine Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-21Ingrid DelaetSELL5000145.06
2024-03-14George J. MorrowSELL40000139.42
2024-03-14Eric BenevichSELL75000139.38
2024-03-11Ingrid DelaetSELL200140
2024-03-11Richard F PopsSELL100140
2024-03-08Ingrid DelaetSELL1800140.03
2024-03-08Richard F PopsSELL1700140.05
2024-02-29Ingrid DelaetSELL273135.51
2024-02-27Leslie V. NorwalkSELL8000135.67
2024-02-20Richard F PopsSELL15000132.47
2024-02-13Eiry RobertsSELL1114132.96
2024-02-13Matt AbernethySELL1352132.85
2024-02-13Kevin Charles GormanSELL2832133.02
2024-02-08David W BoyerSELL1328135.41
2024-02-08Matt AbernethySELL980134.21
2024-02-08Kevin Charles GormanSELL2274134.15
2024-02-06David W BoyerSELL456141.96
2024-02-06Matt AbernethySELL1280142.19
2024-02-06Kevin Charles GormanSELL3040142.18
2024-01-31Eiry RobertsSELL1457140.79

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Neurocrine Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.0151.219+65%0.784+157%0.849+137%0.515+291%
Book Value Per Share--21.81819.261+13%15.187+44%12.302+77%7.955+174%
Current Ratio--2.4542.810-13%3.193-23%4.219-42%9.256-73%
Debt To Asset Ratio--0.3140.297+6%0.300+5%0.382-18%0.323-3%
Debt To Equity Ratio--0.4570.423+8%0.431+6%0.666-31%0.580-21%
Dividend Per Share----0%-0%-0%-0%
Eps--1.4440.612+136%0.385+275%0.468+209%0.130+1007%
Free Cash Flow Per Share--1.1540.889+30%0.807+43%0.635+82%0.261+342%
Free Cash Flow To Equity Per Share--1.5001.050+43%0.217+591%0.497+202%0.435+245%
Gross Profit Margin--1.0001.0000%1.0000%0.777+29%0.889+13%
Intrinsic Value_10Y_max--47.547--------
Intrinsic Value_10Y_min--22.122--------
Intrinsic Value_1Y_max--3.296--------
Intrinsic Value_1Y_min--1.252--------
Intrinsic Value_3Y_max--11.023--------
Intrinsic Value_3Y_min--4.619--------
Intrinsic Value_5Y_max--20.098--------
Intrinsic Value_5Y_min--8.901--------
Market Cap13828557830.880+3%13479048000.00011093451888.720+22%10409265997.440+29%10004015184.000+35%7566353285.394+78%
Net Profit Margin--0.2870.121+138%0.098+192%0.137+110%-0.446+256%
Operating Margin--0.2920.111+163%0.155+88%0.191+53%-0.430+248%
Operating Ratio--0.7080.798-11%0.842-16%0.778-9%1.456-51%
Pb Ratio6.369+5%6.0395.700+6%6.853-12%9.876-39%11.898-49%
Pe Ratio24.063+5%22.81512.224+87%24.171-6%14.739+55%-27.591+221%
Price Per Share138.970+5%131.760109.945+20%104.220+26%100.150+32%75.845+74%
Price To Free Cash Flow Ratio30.094+5%28.5339.320+206%4.469+539%-12.647+144%-14.650+151%
Price To Total Gains Ratio68.967+5%65.389-1743.230+2766%254.292-74%-254.690+489%-97.775+250%
Quick Ratio--3.4384.253-19%4.371-21%6.292-45%14.799-77%
Return On Assets--0.0450.020+131%0.017+169%0.022+103%-0.016+136%
Return On Equity--0.0660.028+133%0.024+180%0.033+98%-0.017+126%
Total Gains Per Share--2.0151.219+65%0.784+157%0.849+137%0.515+291%
Usd Book Value--2232000000.0001942900000.000+15%1516725000.000+47%1230484800.000+81%794803900.000+181%
Usd Book Value Change Per Share--2.0151.219+65%0.784+157%0.849+137%0.515+291%
Usd Book Value Per Share--21.81819.261+13%15.187+44%12.302+77%7.955+174%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--1.4440.612+136%0.385+275%0.468+209%0.130+1007%
Usd Free Cash Flow--118100000.00090400000.000+31%80725000.000+46%63625300.000+86%26220375.000+350%
Usd Free Cash Flow Per Share--1.1540.889+30%0.807+43%0.635+82%0.261+342%
Usd Free Cash Flow To Equity Per Share--1.5001.050+43%0.217+591%0.497+202%0.435+245%
Usd Market Cap13828557830.880+3%13479048000.00011093451888.720+22%10409265997.440+29%10004015184.000+35%7566353285.394+78%
Usd Price Per Share138.970+5%131.760109.945+20%104.220+26%100.150+32%75.845+74%
Usd Profit--147700000.00062425000.000+137%38625000.000+282%46905600.000+215%13153000.000+1023%
Usd Revenue--515200000.000471775000.000+9%372175000.000+38%317168850.000+62%177263750.000+191%
Usd Total Gains Per Share--2.0151.219+65%0.784+157%0.849+137%0.515+291%
 EOD+4 -4MRQTTM+25 -8YOY+26 -75Y+29 -510Y+29 -5

4.2. Fundamental Score

Let's check the fundamental score of Neurocrine Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1524.063
Price to Book Ratio (EOD)Between0-16.369
Net Profit Margin (MRQ)Greater than00.287
Operating Margin (MRQ)Greater than00.292
Quick Ratio (MRQ)Greater than13.438
Current Ratio (MRQ)Greater than12.454
Debt to Asset Ratio (MRQ)Less than10.314
Debt to Equity Ratio (MRQ)Less than10.457
Return on Equity (MRQ)Greater than0.150.066
Return on Assets (MRQ)Greater than0.050.045
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Neurocrine Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.630
Ma 20Greater thanMa 50136.564
Ma 50Greater thanMa 100136.391
Ma 100Greater thanMa 200133.564
OpenGreater thanClose140.890
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -7,9005,200-2,7001,600-1,100-600-1,7008,7007,000



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets3,251,400
Total Liabilities1,019,400
Total Stockholder Equity2,232,000
 As reported
Total Liabilities 1,019,400
Total Stockholder Equity+ 2,232,000
Total Assets = 3,251,400

Assets

Total Assets3,251,400
Total Current Assets1,607,000
Long-term Assets1,644,400
Total Current Assets
Cash And Cash Equivalents 251,100
Short-term Investments 780,500
Net Receivables 439,300
Inventory 38,300
Other Current Assets 97,800
Total Current Assets  (as reported)1,607,000
Total Current Assets  (calculated)1,607,000
+/-0
Long-term Assets
Property Plant Equipment 347,300
Long Term Investments 849,400
Intangible Assets 35,500
Long-term Assets Other 49,600
Long-term Assets  (as reported)1,644,400
Long-term Assets  (calculated)1,281,800
+/- 362,600

Liabilities & Shareholders' Equity

Total Current Liabilities654,800
Long-term Liabilities364,600
Total Stockholder Equity2,232,000
Total Current Liabilities
Short-term Debt 170,100
Short Long Term Debt 170,100
Accounts payable 108,900
Other Current Liabilities 35,900
Total Current Liabilities  (as reported)654,800
Total Current Liabilities  (calculated)485,000
+/- 169,800
Long-term Liabilities
Capital Lease Obligations 258,300
Long-term Liabilities Other 10,300
Long-term Liabilities  (as reported)364,600
Long-term Liabilities  (calculated)268,600
+/- 96,000
Total Stockholder Equity
Common Stock100
Retained Earnings -157,100
Accumulated Other Comprehensive Income 7,000
Other Stockholders Equity 2,382,000
Total Stockholder Equity (as reported)2,232,000
Total Stockholder Equity (calculated)2,232,000
+/-0
Other
Capital Stock100
Cash and Short Term Investments 1,031,600
Common Stock Shares Outstanding 102,300
Current Deferred Revenue339,900
Liabilities and Stockholders Equity 3,251,400
Net Debt 177,300
Net Invested Capital 2,402,100
Net Working Capital 952,200
Property Plant and Equipment Gross 430,300
Short Long Term Debt Total 428,400



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-31
> Total Assets 
28,100
73,400
72,200
78,000
82,900
84,000
84,900
91,900
91,900
83,500
86,900
80,500
74,600
70,600
68,300
109,200
106,399
97,908
96,260
185,962
172,837
163,624
177,954
346,350
328,286
311,367
298,643
266,539
363,044
372,762
552,402
554,955
577,269
546,479
552,619
519,217
486,368
475,512
500,969
483,123
477,403
442,543
404,131
389,677
363,715
341,864
317,498
276,654
243,884
225,670
207,733
118,182
101,028
86,869
75,908
70,818
79,883
155,044
149,933
144,424
133,997
127,405
149,028
138,368
210,141
202,087
193,251
195,979
183,924
174,813
165,967
154,676
279,296
269,539
257,751
243,033
527,779
511,205
492,436
474,785
459,332
429,838
399,161
365,086
289,364
754,086
772,496
817,591
806,360
841,317
933,746
993,151
957,723
1,066,861
1,179,935
1,306,000
1,361,900
1,515,600
1,502,600
1,734,700
1,846,400
1,956,400
2,017,300
2,072,500
2,144,500
2,005,700
2,143,400
2,368,700
2,359,800
2,613,100
2,848,200
3,251,400
3,251,4002,848,2002,613,1002,359,8002,368,7002,143,4002,005,7002,144,5002,072,5002,017,3001,956,4001,846,4001,734,7001,502,6001,515,6001,361,9001,306,0001,179,9351,066,861957,723993,151933,746841,317806,360817,591772,496754,086289,364365,086399,161429,838459,332474,785492,436511,205527,779243,033257,751269,539279,296154,676165,967174,813183,924195,979193,251202,087210,141138,368149,028127,405133,997144,424149,933155,04479,88370,81875,90886,869101,028118,182207,733225,670243,884276,654317,498341,864363,715389,677404,131442,543477,403483,123500,969475,512486,368519,217552,619546,479577,269554,955552,402372,762363,044266,539298,643311,367328,286346,350177,954163,624172,837185,96296,26097,908106,399109,20068,30070,60074,60080,50086,90083,50091,90091,90084,90084,00082,90078,00072,20073,40028,100
   > Total Current Assets 
23,900
68,400
66,300
72,100
76,300
72,600
73,500
76,400
76,400
66,500
67,900
65,600
60,400
56,500
54,200
94,800
92,020
83,102
82,618
172,405
158,884
148,839
162,669
331,515
313,607
294,598
281,116
248,094
341,809
314,298
464,374
471,809
381,650
336,054
336,658
313,815
281,034
271,525
297,628
279,310
274,722
240,627
204,780
193,658
170,313
150,595
128,180
182,948
152,203
113,629
98,810
81,423
67,204
53,784
58,190
55,387
68,332
143,761
131,592
133,051
126,584
120,038
136,126
132,476
184,974
181,258
178,018
189,264
160,395
155,853
159,218
148,462
221,735
197,575
183,868
198,203
404,953
389,416
382,785
384,074
400,984
391,966
357,891
310,442
239,451
536,751
548,485
554,919
513,716
567,677
714,394
737,777
633,192
748,808
819,232
831,000
968,200
1,146,200
1,156,900
1,016,200
1,085,400
1,110,100
1,005,700
972,800
1,018,200
1,019,300
1,205,500
1,453,500
1,432,800
1,496,600
1,649,900
1,607,000
1,607,0001,649,9001,496,6001,432,8001,453,5001,205,5001,019,3001,018,200972,8001,005,7001,110,1001,085,4001,016,2001,156,9001,146,200968,200831,000819,232748,808633,192737,777714,394567,677513,716554,919548,485536,751239,451310,442357,891391,966400,984384,074382,785389,416404,953198,203183,868197,575221,735148,462159,218155,853160,395189,264178,018181,258184,974132,476136,126120,038126,584133,051131,592143,76168,33255,38758,19053,78467,20481,42398,810113,629152,203182,948128,180150,595170,313193,658204,780240,627274,722279,310297,628271,525281,034313,815336,658336,054381,650471,809464,374314,298341,809248,094281,116294,598313,607331,515162,669148,839158,884172,40582,61883,10292,02094,80054,20056,50060,40065,60067,90066,50076,40076,40073,50072,60076,30072,10066,30068,40023,900
       Cash And Cash Equivalents 
0
21,700
7,200
11,300
7,200
22,900
15,100
15,800
15,800
10,600
18,600
11,700
6,200
11,900
7,600
21,300
11,988
2,472
11,163
21,078
27,320
25,431
11,946
163,888
51,314
47,856
56,626
44,313
68,411
34,896
123,820
105,854
38,009
22,735
84,694
61,027
44,570
48,499
75,384
49,948
101,494
86,168
75,760
80,981
78,457
51,485
50,350
99,664
107,639
91,917
80,125
68,467
51,665
38,615
35,316
37,329
52,224
95,120
77,330
54,051
24,393
18,838
39,516
50,107
76,940
42,018
44,488
63,754
31,555
44,313
34,889
44,789
105,532
37,445
29,046
31,014
170,262
132,070
66,378
74,195
115,301
86,246
99,761
83,267
64,087
309,498
267,818
254,712
175,311
166,422
195,734
141,714
72,778
140,985
166,637
112,279
187,000
415,100
944,700
801,000
352,600
368,000
311,100
340,800
270,200
163,300
212,200
262,900
-90,400
160,200
293,700
251,100
251,100293,700160,200-90,400262,900212,200163,300270,200340,800311,100368,000352,600801,000944,700415,100187,000112,279166,637140,98572,778141,714195,734166,422175,311254,712267,818309,49864,08783,26799,76186,246115,30174,19566,378132,070170,26231,01429,04637,445105,53244,78934,88944,31331,55563,75444,48842,01876,94050,10739,51618,83824,39354,05177,33095,12052,22437,32935,31638,61551,66568,46780,12591,917107,63999,66450,35051,48578,45780,98175,76086,168101,49449,94875,38448,49944,57061,02784,69422,73538,009105,854123,82034,89668,41144,31356,62647,85651,314163,88811,94625,43127,32021,07811,1632,47211,98821,3007,60011,9006,20011,70018,60010,60015,80015,80015,10022,9007,20011,3007,20021,7000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,900
69,800
77,763
77,346
68,285
143,592
128,369
118,877
129,309
156,094
254,691
239,614
218,281
200,397
239,828
237,918
318,957
347,314
333,724
303,802
239,653
240,102
226,337
194,769
215,454
223,120
162,995
148,151
124,018
101,623
88,334
95,812
74,483
79,721
42,106
19,984
16,824
12,006
14,710
14,152
21,802
16,135
13,975
36,268
47,641
72,814
97,246
96,322
72,115
78,996
104,146
135,522
129,473
109,259
126,679
109,383
122,022
100,950
114,330
157,211
150,628
162,795
199,745
252,650
310,467
304,996
266,223
301,152
253,281
224,083
171,493
215,522
243,200
261,217
285,168
342,318
439,609
509,199
451,290
478,993
503,525
558,245
584,700
533,200
519,400
613,900
521,100
516,900
454,800
370,500
394,700
485,000
587,200
726,400
1,139,200
816,500
801,400
780,500
780,500801,400816,5001,139,200726,400587,200485,000394,700370,500454,800516,900521,100613,900519,400533,200584,700558,245503,525478,993451,290509,199439,609342,318285,168261,217243,200215,522171,493224,083253,281301,152266,223304,996310,467252,650199,745162,795150,628157,211114,330100,950122,022109,383126,679109,259129,473135,522104,14678,99672,11596,32297,24672,81447,64136,26813,97516,13521,80214,15214,71012,00616,82419,98442,10679,72174,48395,81288,334101,623124,018148,151162,995223,120215,454194,769226,337240,102239,653303,802333,724347,314318,957237,918239,828200,397218,281239,614254,691156,094129,309118,877128,369143,59268,28577,34677,76369,80040,90000000000000000
       Net Receivables 
2,900
5,500
4,500
1,300
3,100
7,700
2,600
200
200
900
1,400
1,400
1,700
2,700
4,600
1,500
722
869
1,265
5,974
1,243
1,985
19,710
9,949
4,895
2,722
2,391
247
29,803
32,221
16,397
13,659
4,563
4,631
7,493
8,213
4,228
22,832
1,538
858
5,930
406
431
7,191
274
35
18
27
12
2
163
39
10
3
12
0
0
11,280
5,219
4,470
3,281
2,912
22,397
1,903
1,809
1,539
1,369
14,089
8
38
75
23
1,873
2,919
0
0
30,030
0
0
0
15,083
0
0
0
0
6,074
29,818
31,127
44,624
42,646
54,097
56,240
71,964
95,357
115,318
126,575
148,600
148,400
156,900
157,100
147,800
158,500
163,800
185,500
263,500
279,000
301,200
350,000
391,600
387,600
417,800
439,300
439,300417,800387,600391,600350,000301,200279,000263,500185,500163,800158,500147,800157,100156,900148,400148,600126,575115,31895,35771,96456,24054,09742,64644,62431,12729,8186,074000015,08300030,030002,9191,873237538814,0891,3691,5391,8091,90322,3972,9123,2814,4705,21911,2800012310391632122718352747,1914314065,9308581,53822,8324,2288,2137,4934,6314,56313,65916,39732,22129,8032472,3912,7224,8959,94919,7101,9851,2435,9741,2658697221,5004,6002,7001,7001,4001,4009002002002,6007,7003,1001,3004,5005,5002,900
       Other Current Assets 
21,000
41,200
54,600
59,500
66,000
42,000
55,800
0
60,400
55,000
47,900
52,500
52,500
41,900
1,100
2,200
1,547
2,415
1,905
1,761
1,952
2,546
1,704
1,584
2,707
4,406
3,818
3,137
3,767
9,263
5,200
4,982
5,354
4,886
4,818
4,473
5,899
5,425
5,252
5,384
4,303
5,902
4,571
3,863
3,248
3,263
3,329
3,536
2,446
1,726
1,698
911
819
1,014
1,060
1,923
2,133
132,481
126,373
1,716
1,664
1,966
2,098
1,470
2,079
2,179
2,688
16,251
2,153
2,157
2,232
2,723
1,873
2,919
4,194
4,394
34,946
4,696
5,940
4,883
4,377
4,568
4,849
3,092
3,871
5,529
7,407
38,990
8,613
16,291
18,900
86,864
24,150
21,455
22,954
160,500
26,700
27,500
212,200
215,200
33,800
38,400
50,500
261,500
60,800
62,700
67,900
464,200
538,200
519,900
554,800
97,800
97,800554,800519,900538,200464,20067,90062,70060,800261,50050,50038,40033,800215,200212,20027,50026,700160,50022,95421,45524,15086,86418,90016,2918,61338,9907,4075,5293,8713,0924,8494,5684,3774,8835,9404,69634,9464,3944,1942,9191,8732,7232,2322,1572,15316,2512,6882,1792,0791,4702,0981,9661,6641,716126,373132,4812,1331,9231,0601,0148199111,6981,7262,4463,5363,3293,2633,2483,8634,5715,9024,3035,3845,2525,4255,8994,4734,8184,8865,3544,9825,2009,2633,7673,1373,8184,4062,7071,5841,7042,5461,9521,7611,9052,4151,5472,2001,10041,90052,50052,50047,90055,00060,400055,80042,00066,00059,50054,60041,20021,000
   > Long-term Assets 
4,200
5,000
5,900
5,900
6,600
11,400
11,400
0
15,500
17,000
19,000
14,900
14,200
14,100
14,100
14,400
14,379
14,806
13,642
13,557
13,953
14,785
15,285
14,835
14,679
16,769
17,527
18,445
21,235
58,464
88,028
83,146
195,619
210,425
215,961
205,402
205,334
203,987
203,341
203,813
202,681
201,916
199,351
196,019
193,402
191,269
189,318
93,706
91,681
112,041
108,923
36,759
33,824
33,085
17,718
15,431
11,551
11,283
18,341
11,373
7,413
7,367
12,902
5,892
25,167
20,829
15,233
6,715
23,529
18,960
6,749
6,214
57,561
71,964
73,883
44,830
122,826
121,789
109,651
90,711
58,348
37,872
41,270
54,644
49,913
217,335
224,011
262,672
292,644
273,640
219,352
255,374
324,531
318,053
360,703
475,000
393,700
369,400
345,700
718,500
761,000
846,300
1,011,600
1,099,700
1,126,300
986,400
937,900
915,200
927,000
1,116,500
1,198,300
1,644,400
1,644,4001,198,3001,116,500927,000915,200937,900986,4001,126,3001,099,7001,011,600846,300761,000718,500345,700369,400393,700475,000360,703318,053324,531255,374219,352273,640292,644262,672224,011217,33549,91354,64441,27037,87258,34890,711109,651121,789122,82644,83073,88371,96457,5616,2146,74918,96023,5296,71515,23320,82925,1675,89212,9027,3677,41311,37318,34111,28311,55115,43117,71833,08533,82436,759108,923112,04191,68193,706189,318191,269193,402196,019199,351201,916202,681203,813203,341203,987205,334205,402215,961210,425195,61983,14688,02858,46421,23518,44517,52716,76914,67914,83515,28514,78513,95313,55713,64214,80614,37914,40014,10014,10014,20014,90019,00017,00015,500011,40011,4006,6005,9005,9005,0004,200
       Property Plant Equipment 
2,700
3,100
3,500
3,500
3,800
5,500
5,300
8,800
8,800
9,900
7,300
10,900
10,900
11,100
11,500
11,200
11,195
11,371
11,166
11,300
11,510
12,141
12,653
12,088
11,723
13,037
13,708
14,102
14,372
48,407
58,289
56,236
79,044
93,957
98,985
102,166
101,238
99,811
98,937
99,307
97,363
96,693
93,868
91,378
88,882
86,524
84,631
82,598
80,672
79,434
77,309
6,191
5,075
4,183
3,395
2,695
2,236
2,085
1,827
1,532
1,309
1,263
1,687
1,586
1,837
1,861
2,034
1,900
1,784
1,876
1,739
1,771
1,798
2,239
2,292
2,507
2,543
2,802
2,874
3,432
3,897
5,811
6,180
6,271
7,144
6,954
9,140
10,811
11,825
18,775
28,618
33,869
85,965
88,708
102,289
116,200
115,200
116,700
114,000
127,400
142,300
150,300
149,000
155,800
158,600
159,000
150,500
145,600
147,200
149,100
149,600
347,300
347,300149,600149,100147,200145,600150,500159,000158,600155,800149,000150,300142,300127,400114,000116,700115,200116,200102,28988,70885,96533,86928,61818,77511,82510,8119,1406,9547,1446,2716,1805,8113,8973,4322,8742,8022,5432,5072,2922,2391,7981,7711,7391,8761,7841,9002,0341,8611,8371,5861,6871,2631,3091,5321,8272,0852,2362,6953,3954,1835,0756,19177,30979,43480,67282,59884,63186,52488,88291,37893,86896,69397,36399,30798,93799,811101,238102,16698,98593,95779,04456,23658,28948,40714,37214,10213,70813,03711,72312,08812,65312,14111,51011,30011,16611,37111,19511,20011,50011,10010,90010,9007,3009,9008,8008,8005,3005,5003,8003,5003,5003,1002,700
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,087
0
19,024
14,634
8,865
480
17,410
12,749
675
0
51,320
65,282
67,148
37,492
115,452
114,172
101,986
82,488
49,460
27,178
30,207
43,490
37,686
205,768
210,258
247,361
276,319
249,388
185,257
216,028
176,689
146,503
204,793
299,654
235,900
195,200
181,400
227,100
249,600
376,700
549,000
560,700
541,000
405,200
457,500
401,500
380,300
342,600
587,500
849,400
849,400587,500342,600380,300401,500457,500405,200541,000560,700549,000376,700249,600227,100181,400195,200235,900299,654204,793146,503176,689216,028185,257249,388276,319247,361210,258205,76837,68643,49030,20727,17849,46082,488101,986114,172115,45237,49267,14865,28251,320067512,74917,4104808,86514,63419,02405,08700000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
1,000
1,300
1,300
1,400
1,400
1,400
1,300
1,200
1,200
1,100
0
1,000
0
0
0
600
0
0
0
362
323
284
0
188
155
121
98
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,400
0
0
0
0
0
0
0
18,400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,200
37,200
36,900
34,900
35,500
35,50034,90036,90037,20037,200000000000000000000000000000000000000000000018,400000000023,40000000000000000000000000000009812115518802843233620006000001,00001,1001,2001,2001,3001,4001,4001,4001,3001,3001,000
       Long-term Assets Other 
500
600
1,100
1,000
1,400
4,500
4,800
5,500
5,500
6,000
11,700
3,000
3,300
3,000
2,600
2,600
3,184
3,435
2,476
1,895
2,120
2,360
2,632
2,559
2,801
3,611
3,721
4,343
6,863
10,057
29,739
26,910
116,575
116,468
116,976
103,236
104,096
104,176
104,404
104,506
105,318
105,223
105,483
104,641
104,520
104,745
104,687
11,108
11,009
11,014
10,359
30,568
9,140
7,660
7,721
-78,975
6,327
6,329
6,333
6,102
6,104
6,104
6,128
4,306
4,306
4,334
4,334
4,335
4,335
4,335
4,335
4,443
4,443
4,443
4,443
4,831
4,831
4,815
4,791
4,791
4,991
4,883
4,883
4,883
5,083
4,613
4,613
4,500
4,500
5,477
5,477
5,477
5,477
5,477
4,706
3,200
3,200
6,800
6,600
6,400
4,600
3,200
3,200
4,400
10,100
10,000
10,500
25,000
24,900
35,900
43,100
49,600
49,60043,10035,90024,90025,00010,50010,00010,1004,4003,2003,2004,6006,4006,6006,8003,2003,2004,7065,4775,4775,4775,4775,4774,5004,5004,6134,6135,0834,8834,8834,8834,9914,7914,7914,8154,8314,8314,4434,4434,4434,4434,3354,3354,3354,3354,3344,3344,3064,3066,1286,1046,1046,1026,3336,3296,327-78,9757,7217,6609,14030,56810,35911,01411,00911,108104,687104,745104,520104,641105,483105,223105,318104,506104,404104,176104,096103,236116,976116,468116,57526,91029,73910,0576,8634,3433,7213,6112,8012,5592,6322,3602,1201,8952,4763,4353,1842,6002,6003,0003,3003,00011,7006,0005,5005,5004,8004,5001,4001,0001,100600500
> Total Liabilities 
3,900
4,900
4,000
5,200
5,700
6,600
6,400
8,700
8,700
5,100
8,200
8,500
6,600
7,300
9,000
12,800
14,361
11,055
14,825
22,754
19,545
20,759
32,421
35,957
34,352
34,136
38,812
42,285
147,831
162,793
165,573
163,835
151,864
134,938
140,055
125,390
111,648
103,493
97,229
93,019
93,573
80,771
77,655
74,961
72,012
72,815
72,544
157,957
145,218
145,829
144,086
81,408
81,917
79,521
74,833
66,864
63,162
142,632
133,286
125,079
111,003
101,847
91,279
78,287
66,307
57,354
49,946
41,607
38,971
38,797
36,675
34,266
32,239
32,694
33,714
34,334
43,049
44,265
45,493
50,331
46,373
48,800
47,510
50,209
42,223
408,848
424,984
445,453
441,873
463,881
486,233
512,386
548,448
583,155
605,420
669,100
661,600
684,400
698,300
608,500
640,800
677,200
671,300
698,500
753,400
582,300
598,800
660,900
675,300
760,100
846,100
1,019,400
1,019,400846,100760,100675,300660,900598,800582,300753,400698,500671,300677,200640,800608,500698,300684,400661,600669,100605,420583,155548,448512,386486,233463,881441,873445,453424,984408,84842,22350,20947,51048,80046,37350,33145,49344,26543,04934,33433,71432,69432,23934,26636,67538,79738,97141,60749,94657,35466,30778,28791,279101,847111,003125,079133,286142,63263,16266,86474,83379,52181,91781,408144,086145,829145,218157,95772,54472,81572,01274,96177,65580,77193,57393,01997,229103,493111,648125,390140,055134,938151,864163,835165,573162,793147,83142,28538,81234,13634,35235,95732,42120,75919,54522,75414,82511,05514,36112,8009,0007,3006,6008,5008,2005,1008,7008,7006,4006,6005,7005,2004,0004,9003,900
   > Total Current Liabilities 
2,200
3,400
2,700
4,100
4,500
5,500
5,300
7,400
7,400
3,400
5,100
5,600
3,700
3,700
5,000
8,600
9,930
7,074
10,377
14,959
12,093
12,847
22,410
24,761
23,655
23,628
29,608
32,479
97,085
101,612
115,274
110,012
97,536
67,503
72,112
59,585
47,182
40,294
35,039
33,693
32,757
23,932
21,267
20,116
17,823
18,943
20,021
29,907
17,972
19,494
18,975
26,094
32,536
33,017
24,044
19,961
18,630
52,123
53,184
52,777
49,028
49,990
48,444
47,110
36,631
29,152
23,113
15,646
13,878
14,573
13,321
11,699
10,608
12,053
14,045
15,664
15,187
17,553
19,822
25,715
23,276
26,899
26,666
30,414
23,563
27,721
38,141
54,426
46,466
61,762
456,400
88,233
72,003
100,589
115,652
565,300
140,300
573,000
611,000
186,500
190,000
212,900
225,900
245,800
253,500
285,700
485,100
537,700
374,100
582,500
691,600
654,800
654,800691,600582,500374,100537,700485,100285,700253,500245,800225,900212,900190,000186,500611,000573,000140,300565,300115,652100,58972,00388,233456,40061,76246,46654,42638,14127,72123,56330,41426,66626,89923,27625,71519,82217,55315,18715,66414,04512,05310,60811,69913,32114,57313,87815,64623,11329,15236,63147,11048,44449,99049,02852,77753,18452,12318,63019,96124,04433,01732,53626,09418,97519,49417,97229,90720,02118,94317,82320,11621,26723,93232,75733,69335,03940,29447,18259,58572,11267,50397,536110,012115,274101,61297,08532,47929,60823,62823,65524,76122,41012,84712,09314,95910,3777,0749,9308,6005,0003,7003,7005,6005,1003,4007,4007,4005,3005,5004,5004,1002,7003,4002,200
       Short-term Debt 
800
0
0
800
0
0
0
900
900
0
0
800
1,500
0
900
1,000
990
1,006
1,147
1,587
1,548
1,741
1,694
2,087
1,887
1,956
2,216
2,658
2,939
3,344
3,422
3,960
4,034
3,946
4,752
6,674
6,458
6,234
6,052
5,814
5,547
5,246
4,863
4,489
3,877
3,271
2,691
1,486
1,025
601
276
10,905
15,202
15,414
8,898
4,289
4,369
4,450
4,047
8,603
8,862
10,311
10,581
8,451
10,031
10,024
11,240
11,227
9,733
11,364
11,085
0
0
0
0
0
3,207
5,731
7,913
12,495
10,689
14,647
14,451
14,862
12,237
360,681
365,110
38,372
374,209
378,885
383,647
62,345
3,267
0
0
408,800
0
419,500
425,000
94,000
770,000
120,000
289,000
225,000
0
17,100
169,200
169,400
18,400
169,700
169,900
170,100
170,100169,900169,70018,400169,400169,20017,1000225,000289,000120,000770,00094,000425,000419,5000408,800003,26762,345383,647378,885374,20938,372365,110360,68112,23714,86214,45114,64710,68912,4957,9135,7313,2070000011,08511,3649,73311,22711,24010,02410,0318,45110,58110,3118,8628,6034,0474,4504,3694,2898,89815,41415,20210,9052766011,0251,4862,6913,2713,8774,4894,8635,2465,5475,8146,0526,2346,4586,6744,7523,9464,0343,9603,4223,3442,9392,6582,2161,9561,8872,0871,6941,7411,5481,5871,1471,0069901,00090001,5008000090090000080000800
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
360,681
365,110
369,618
374,209
378,885
383,647
88,233
3,267
0
0
408,807
0
419,500
425,000
0
0
0
0
0
0
0
169,200
169,400
0
169,700
169,900
170,100
170,100169,900169,7000169,400169,2000000000425,000419,5000408,807003,26788,233383,647378,885374,209369,618365,110360,6810000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
200
1,100
600
800
900
500
1,700
0
1,800
600
1,100
2,500
700
1,200
800
2,400
1,741
700
783
1,065
658
731
1,354
1,539
868
1,445
3,669
1,959
2,163
2,717
1,912
1,295
2,910
27,119
29,573
5,391
18,733
17,716
18,091
3,447
16,791
17,233
15,428
3,213
13,910
15,663
17,294
3,776
1,408
2,739
2,988
1,599
2,551
1,752
1,501
2,188
539
640
912
810
507
932
766
1,111
596
1,420
1,416
911
1,460
1,348
1,097
101
818
846
900
246
1,270
1,035
1,197
2,561
2,122
1,762
1,719
5,085
852
26,809
37,289
5,648
45,650
61,031
61,791
13,801
68,280
95,027
102,357
46,214
125,900
137,100
170,500
39,400
171,900
190,900
205,900
51,500
235,900
265,700
297,800
76,300
355,700
391,600
93,800
108,900
108,90093,800391,600355,70076,300297,800265,700235,90051,500205,900190,900171,90039,400170,500137,100125,90046,214102,35795,02768,28013,80161,79161,03145,6505,64837,28926,8098525,0851,7191,7622,1222,5611,1971,0351,2702469008468181011,0971,3481,4609111,4161,4205961,1117669325078109126405392,1881,5011,7522,5511,5992,9882,7391,4083,77617,29415,66313,9103,21315,42817,23316,7913,44718,09117,71618,7335,39129,57327,1192,9101,2951,9122,7172,1631,9593,6691,4458681,5391,3547316581,0657837001,7412,4008001,2007002,5001,1006001,80001,7005009008006001,100200
       Other Current Liabilities 
1,200
2,300
2,100
2,500
3,600
5,000
3,600
0
4,700
2,800
4,000
2,300
1,500
2,500
3,300
5,200
7,199
5,368
8,447
12,307
8,242
8,788
11,119
15,753
15,976
17,604
15,504
22,163
34,602
47,968
58,524
55,091
42,676
36,438
37,787
19,846
21,991
16,344
10,896
17,895
10,419
1,453
976
12,414
36
9
36
21,717
12,620
13,235
12,785
10,654
11,861
12,930
10,716
10,543
10,797
10,082
11,265
3,385
2,701
2,004
1,604
264
269
273
280
589
496
402
409
11,598
9,790
11,207
13,145
15,418
479
556
481
428
234
259
265
236
243
17,490
27,910
175
36,235
51,531
731
1,856
72,003
100,589
115,652
156,500
140,300
153,500
186,000
147,100
190,000
212,900
225,900
194,300
253,500
285,700
315,900
292,000
374,100
412,800
521,700
35,900
35,900521,700412,800374,100292,000315,900285,700253,500194,300225,900212,900190,000147,100186,000153,500140,300156,500115,652100,58972,0031,85673151,53136,23517527,91017,49024323626525923442848155647915,41813,14511,2079,79011,5984094024965892802732692641,6042,0042,7013,38511,26510,08210,79710,54310,71612,93011,86110,65412,78513,23512,62021,7173693612,4149761,45310,41917,89510,89616,34421,99119,84637,78736,43842,67655,09158,52447,96834,60222,16315,50417,60415,97615,75311,1198,7888,24212,3078,4475,3687,1995,2003,3002,5001,5002,3004,0002,8004,70003,6005,0003,6002,5002,1002,3001,200
   > Long-term Liabilities 
1,700
1,500
1,300
1,100
1,200
1,100
1,100
0
1,300
1,700
3,100
2,900
2,900
3,600
4,000
4,200
4,431
3,981
4,448
7,795
7,452
7,912
10,011
11,196
10,697
10,508
9,204
9,806
50,746
61,181
50,299
53,823
54,328
67,435
67,943
65,805
64,466
63,199
62,190
59,326
60,816
56,839
56,388
54,845
54,189
53,872
52,523
128,050
127,246
126,335
125,111
55,314
49,381
46,504
50,789
46,903
44,532
90,509
80,102
72,302
61,975
51,857
42,835
31,177
29,676
28,202
26,833
25,961
25,093
24,224
23,354
22,567
21,631
20,641
19,669
18,670
27,862
26,712
25,671
24,616
23,097
21,901
20,844
19,795
18,660
381,127
386,843
391,027
395,407
402,119
29,833
424,153
476,445
482,566
489,768
103,800
521,300
111,400
87,300
422,000
450,800
464,300
445,400
452,700
499,900
296,600
113,700
123,200
301,200
177,600
154,500
364,600
364,600154,500177,600301,200123,200113,700296,600499,900452,700445,400464,300450,800422,00087,300111,400521,300103,800489,768482,566476,445424,15329,833402,119395,407391,027386,843381,12718,66019,79520,84421,90123,09724,61625,67126,71227,86218,67019,66920,64121,63122,56723,35424,22425,09325,96126,83328,20229,67631,17742,83551,85761,97572,30280,10290,50944,53246,90350,78946,50449,38155,314125,111126,335127,246128,05052,52353,87254,18954,84556,38856,83960,81659,32662,19063,19964,46665,80567,94367,43554,32853,82350,29961,18150,7469,8069,20410,50810,69711,19610,0117,9127,4527,7954,4483,9814,4314,2004,0003,6002,9002,9003,1001,7001,30001,1001,1001,2001,1001,3001,5001,700
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
360,681
365,110
369,618
374,209
378,885
0
388,496
393,435
398,466
403,589
408,807
414,100
0
0
317,900
322,000
326,300
330,700
335,100
377,700
169,000
0
0
169,500
0
0
0
000169,50000169,000377,700335,100330,700326,300322,000317,90000414,100408,807403,589398,466393,435388,4960378,885374,209369,618365,110360,6810000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,547
2,354
2,538
5,512
5,476
5,489
7,969
7,596
7,469
6,873
4,731
4,529
45,383
42,058
31,194
21,350
11,232
12,501
3,997
6,353
6,516
6,799
7,249
5,736
8,413
5,634
6,259
5,693
5,663
5,939
5,085
19,305
18,501
17,590
16,366
55,314
49,381
46,504
50,789
46,903
44,532
90,509
80,102
72,302
61,975
51,857
42,835
31,177
29,676
28,202
26,833
25,961
25,093
24,224
23,354
22,567
21,631
20,641
19,669
18,670
27,862
26,712
25,671
24,616
23,097
21,901
20,844
19,795
18,660
20,446
21,733
21,409
21,198
23,234
29,833
35,657
15,863
17,915
11,697
17,074
21,600
27,100
4,300
9,700
21,300
29,000
8,300
12,300
19,700
28,000
17,100
29,700
41,300
0
0
0
00041,30029,70017,10028,00019,70012,3008,30029,00021,3009,7004,30027,10021,60017,07411,69717,91515,86335,65729,83323,23421,19821,40921,73320,44618,66019,79520,84421,90123,09724,61625,67126,71227,86218,67019,66920,64121,63122,56723,35424,22425,09325,96126,83328,20229,67631,17742,83551,85761,97572,30280,10290,50944,53246,90350,78946,50449,38155,31416,36617,59018,50119,3055,0855,9395,6635,6936,2595,6348,4135,7367,2496,7996,5166,3533,99712,50111,23221,35031,19442,05845,3834,5294,7316,8737,4697,5967,9695,4895,4765,5122,5382,3542,5470000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46,052
37,376
28,724
27,293
25,861
24,412
22,712
21,945
21,179
20,413
19,627
18,805
17,930
17,075
16,199
25,516
24,697
23,781
22,840
22,067
21,075
20,082
19,065
18,003
20,333
21,620
21,409
21,198
23,234
29,833
35,657
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000035,65729,83323,23421,19821,40921,62020,33318,00319,06520,08221,07522,06722,84023,78124,69725,51616,19917,07517,93018,80519,62720,41321,17921,94522,71224,41225,86127,29328,72437,37646,0520000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
24,200
68,500
68,200
72,800
77,200
77,400
78,500
0
83,200
78,400
78,700
72,000
68,000
63,300
59,300
96,400
92,038
86,853
81,435
163,208
153,292
142,865
145,533
310,393
293,934
277,231
259,831
224,254
215,213
209,969
386,829
391,120
425,405
411,541
412,564
393,827
374,720
372,019
403,740
390,104
383,830
361,772
326,476
314,716
291,703
269,049
244,954
118,697
98,666
79,841
63,647
36,774
19,111
7,348
1,075
3,954
16,721
12,412
16,647
19,345
22,994
25,558
57,749
60,081
143,834
144,733
143,305
154,372
144,953
136,016
129,292
120,410
247,057
236,845
224,037
208,699
484,730
466,940
446,943
424,454
412,959
381,038
351,651
314,877
247,141
345,238
347,512
372,138
364,487
377,436
447,513
480,765
409,275
483,706
574,515
636,900
700,300
831,200
804,300
1,126,200
1,205,600
1,279,200
1,346,000
1,374,000
1,391,100
1,423,400
1,544,600
1,707,800
1,684,500
1,853,000
2,002,100
2,232,000
2,232,0002,002,1001,853,0001,684,5001,707,8001,544,6001,423,4001,391,1001,374,0001,346,0001,279,2001,205,6001,126,200804,300831,200700,300636,900574,515483,706409,275480,765447,513377,436364,487372,138347,512345,238247,141314,877351,651381,038412,959424,454446,943466,940484,730208,699224,037236,845247,057120,410129,292136,016144,953154,372143,305144,733143,83460,08157,74925,55822,99419,34516,64712,41216,7213,9541,0757,34819,11136,77463,64779,84198,666118,697244,954269,049291,703314,716326,476361,772383,830390,104403,740372,019374,720393,827412,564411,541425,405391,120386,829209,969215,213224,254259,831277,231293,934310,393145,533142,865153,292163,20881,43586,85392,03896,40059,30063,30068,00072,00078,70078,40083,200078,50077,40077,20072,80068,20068,50024,200
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22
22
22
25
25
26
26
30
30
30
31
31
31
31
35
35
36
36
36
37
37
37
37
37
38
38
38
38
38
38
38
38
38
38
39
39
39
39
39
44
55
55
55
55
55
55
55
55
66
66
66
66
67
67
67
67
76
76
76
76
85
86
86
86
87
87
87
87
88
88
88
89
90
90
91
91
91
92
92
92
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
10010010010010010010010010010010010010010010010092929291919190908988888887878787868686857676767667676767666666665555555555555555443939393939383838383838383838383737373737363636353531313131303030262625252222220000000000000000
   Retained Earnings -157,100-304,800-387,900-483,400-406,800-495,800-564,300-547,400-635,800-628,500-651,000-693,300-725,400-1,073,300-1,015,700-1,095,300-1,132,700-1,166,700-1,220,489-1,271,827-1,177,755-1,195,833-1,246,597-1,240,684-1,198,866-1,205,760-1,194,635-1,134,650-1,056,324-1,011,665-974,778-934,498-915,234-885,919-851,484-827,497-826,305-806,861-790,986-777,605-765,763-755,121-743,990-731,748-719,673-729,163-726,085-725,584-724,698-726,029-757,411-759,387-762,269-764,756-768,089-762,937-754,301-746,385-738,208-722,928-703,263-674,409-656,698-635,727-614,650-486,675-459,435-433,071-407,351-392,639-353,496-326,047-300,146-276,238-302,389-296,785-277,955-257,340-255,693-244,562-232,182-235,375-225,541-215,316-201,926-163,139-142,905-123,154-107,390-92,780-95,287-81,943-70,480-61,046-52,911-47,719-41,700-38,000-33,500-28,900-24,900-18,100-14,100-4,900-4,900-5,000-5,800-5,900-10,000-14,500-14,100-15,900
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
782,933
783,882
784,811
869,479
870,895
872,383
873,981
876,678
879,983
884,355
886,101
1,024,780
1,027,881
1,031,029
1,035,205
1,312,321
1,318,742
1,333,385
1,340,579
1,347,558
1,355,768
1,363,416
1,371,432
1,381,938
1,540,498
1,553,718
1,572,765
1,608,778
1,626,752
1,645,311
1,660,361
1,681,244
1,703,458
1,739,517
1,768,118
1,796,900
1,842,200
1,874,300
1,849,700
1,897,800
1,929,400
1,974,000
2,011,400
1,947,700
1,999,800
2,054,300
2,122,400
2,170,500
2,241,900
0
0
002,241,9002,170,5002,122,4002,054,3001,999,8001,947,7002,011,4001,974,0001,929,4001,897,8001,849,7001,874,3001,842,2001,796,9001,768,1181,739,5171,703,4581,681,2441,660,3611,645,3111,626,7521,608,7781,572,7651,553,7181,540,4981,381,9381,371,4321,363,4161,355,7681,347,5581,340,5791,333,3851,318,7421,312,3211,035,2051,031,0291,027,8811,024,780886,101884,355879,983876,678873,981872,383870,895869,479784,811783,882782,9330000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
40,100
82,600
84,000
84,800
85,100
85,200
85,500
0
91,100
96,200
100,900
101,100
101,600
101,800
97,900
138,700
140,263
140,753
142,798
233,565
235,354
238,393
238,287
420,018
420,574
421,507
422,205
424,084
428,286
432,279
620,724
622,526
668,713
670,183
671,543
674,034
674,468
676,371
681,941
691,717
710,839
716,230
719,405
721,930
724,412
727,446
730,386
733,542
735,355
738,011
739,761
741,568
743,000
744,479
746,178
757,002
778,603
779,446
780,348
781,607
782,326
782,914
783,723
784,811
869,352
870,752
872,383
873,981
876,634
879,939
884,346
886,101
1,024,586
1,027,755
1,030,822
1,035,205
1,312,142
1,318,338
1,333,385
1,340,579
1,347,370
1,355,729
1,363,229
1,371,432
1,381,703
1,540,498
1,553,718
1,572,765
1,608,778
1,626,752
1,645,255
1,660,361
1,681,011
1,703,103
1,739,123
1,768,095
1,796,900
1,842,200
1,874,300
1,849,700
1,897,800
1,929,400
1,974,000
2,011,400
1,947,700
1,999,800
2,054,300
2,122,400
2,170,500
2,241,900
2,308,500
2,382,000
2,382,0002,308,5002,241,9002,170,5002,122,4002,054,3001,999,8001,947,7002,011,4001,974,0001,929,4001,897,8001,849,7001,874,3001,842,2001,796,9001,768,0951,739,1231,703,1031,681,0111,660,3611,645,2551,626,7521,608,7781,572,7651,553,7181,540,4981,381,7031,371,4321,363,2291,355,7291,347,3701,340,5791,333,3851,318,3381,312,1421,035,2051,030,8221,027,7551,024,586886,101884,346879,939876,634873,981872,383870,752869,352784,811783,723782,914782,326781,607780,348779,446778,603757,002746,178744,479743,000741,568739,761738,011735,355733,542730,386727,446724,412721,930719,405716,230710,839691,717681,941676,371674,468674,034671,543670,183668,713622,526620,724432,279428,286424,084422,205421,507420,574420,018238,287238,393235,354233,565142,798140,753140,263138,70097,900101,800101,600101,100100,90096,20091,100085,50085,20085,10084,80084,00082,60040,100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,887,100
Cost of Revenue-39,700
Gross Profit1,847,4001,847,400
 
Operating Income (+$)
Gross Profit1,847,400
Operating Expense-1,452,600
Operating Income250,900394,800
 
Operating Expense (+$)
Research Development565,000
Selling General Administrative851,600
Selling And Marketing Expenses0
Operating Expense1,452,6001,416,600
 
Net Interest Income (+$)
Interest Income0
Interest Expense-4,600
Other Finance Cost-0
Net Interest Income-4,600
 
Pretax Income (+$)
Operating Income250,900
Net Interest Income-4,600
Other Non-Operating Income Expenses0
Income Before Tax (EBT)332,100309,000
EBIT - interestExpense = 390,200
332,100
254,300
Interest Expense4,600
Earnings Before Interest and Taxes (EBIT)394,800336,700
Earnings Before Interest and Taxes (EBITDA)416,100
 
After tax Income (+$)
Income Before Tax332,100
Tax Provision-60,800
Net Income From Continuing Ops191,000271,300
Net Income249,700
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,492,300
Total Other Income/Expenses Net-58,1004,600
 

Technical Analysis of Neurocrine
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neurocrine. The general trend of Neurocrine is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neurocrine's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Neurocrine Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 141.45 < 148.37.

The bearish price targets are: 129.50 > 129.29 > 129.15.

Tweet this
Neurocrine Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Neurocrine Biosciences Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Neurocrine Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Neurocrine Biosciences Inc. The current macd is -0.49347986.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neurocrine price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Neurocrine. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Neurocrine price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Neurocrine Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartNeurocrine Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Neurocrine Biosciences Inc. The current adx is 19.17.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Neurocrine shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Neurocrine Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Neurocrine Biosciences Inc. The current sar is 130.43.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Neurocrine Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Neurocrine Biosciences Inc. The current rsi is 55.63. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Neurocrine Biosciences Inc Daily Relative Strength Index (RSI) ChartNeurocrine Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Neurocrine Biosciences Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neurocrine price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Neurocrine Biosciences Inc Daily Stochastic Oscillator ChartNeurocrine Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Neurocrine Biosciences Inc. The current cci is 98.83.

Neurocrine Biosciences Inc Daily Commodity Channel Index (CCI) ChartNeurocrine Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Neurocrine Biosciences Inc. The current cmo is 19.58.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Neurocrine Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartNeurocrine Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Neurocrine Biosciences Inc. The current willr is -40.55144586.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Neurocrine is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Neurocrine Biosciences Inc Daily Williams %R ChartNeurocrine Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Neurocrine Biosciences Inc. The current atr is 4.4155261.

Neurocrine Biosciences Inc Daily Average True Range (ATR) ChartNeurocrine Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Neurocrine Biosciences Inc. The current obv is 27,332,880.

Neurocrine Biosciences Inc Daily On-Balance Volume (OBV) ChartNeurocrine Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Neurocrine Biosciences Inc. The current mfi is 33.52.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Neurocrine Biosciences Inc Daily Money Flow Index (MFI) ChartNeurocrine Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Neurocrine Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Neurocrine Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Neurocrine Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.630
Ma 20Greater thanMa 50136.564
Ma 50Greater thanMa 100136.391
Ma 100Greater thanMa 200133.564
OpenGreater thanClose140.890
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Neurocrine with someone you think should read this too:
  • Are you bullish or bearish on Neurocrine? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neurocrine? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Neurocrine Biosciences Inc

I send you an email if I find something interesting about Neurocrine Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Neurocrine Biosciences Inc.

Receive notifications about Neurocrine Biosciences Inc in your mailbox!